Mode and site of action of therapies targeting CGRP signaling

Alejandro Labastida-Ramírez; Edoardo Caronna; Cédric Gollion; Emily Stanyer; Austeja Dapkute; Diana Braniste; Hoda Naghshineh; Liga Meksa; Nino Chkhitunidze; Tamari Gudadze; Patricia Pozo-Rosich; Rami Burstein; Jan Hoffmann

doi:10.1186/s10194-023-01644-8

The Journal of Headache and Pain (Sep 2023)

Mode and site of action of therapies targeting CGRP signaling

Alejandro Labastida-Ramírez,
Edoardo Caronna,
Cédric Gollion,
Emily Stanyer,
Austeja Dapkute,
Diana Braniste,
Hoda Naghshineh,
Liga Meksa,
Nino Chkhitunidze,
Tamari Gudadze,
Patricia Pozo-Rosich,
Rami Burstein,
Jan Hoffmann

Affiliations

Alejandro Labastida-Ramírez: Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London
Edoardo Caronna: Headache Unit, Neurology Department, Vall d’Hebron Universitary Hospital
Cédric Gollion: Department of Neurology, University Hospital of Toulouse
Emily Stanyer: Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London
Austeja Dapkute: Centre of Neurology, Vilnius University
Diana Braniste: Institute of Neurology and Neurosurgery
Hoda Naghshineh: Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Science
Liga Meksa: Headache Unit, Neurology and Neurosurgery Department, Riga East University Hospital Gailezers
Nino Chkhitunidze: Department of Neurology, Caucasus Medical Centre
Tamari Gudadze: Department of Neurology, Christian Hospital Unna
Patricia Pozo-Rosich: Headache Unit, Neurology Department, Vall d’Hebron Universitary Hospital
Rami Burstein: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center
Jan Hoffmann: Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London

DOI: https://doi.org/10.1186/s10194-023-01644-8
Journal volume & issue: Vol. 24, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

Published in The Journal of Headache and Pain

ISSN: 1129-2369 (Print); 1129-2377 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://thejournalofheadacheandpain.biomedcentral.com/

About the journal

Abstract

Keywords